<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723320</url>
  </required_header>
  <id_info>
    <org_study_id>2006BAI01A02-03</org_study_id>
    <nct_id>NCT00723320</nct_id>
  </id_info>
  <brief_title>Effect of Atorvastatin and Lifestyle Intervention on Progression of Pre-Clinical Atherosclerosis</brief_title>
  <acronym>EALIPPCA</acronym>
  <official_title>Effect of Atorvastatin and Lifestyle Intervention on Progression of Carotid Intima-Media Thickness in Chinese People Without Manifest Atherosclerotic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Science and Technology of the People´s Republic of China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether atorvastatin, aggressive lifestyle
      intervention, and their interaction are effective in delaying the progress of pre-clinical
      atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary prevention of atherosclerotic disease remains a big challenge. Currently, it is not
      clear how to treat those subjects with evidence of pre-clinical atherosclerosis but without
      obvious conventional risk factors. This randomized, placebo controlled, double blind study is
      to evaluate the effect of Atorvastatin 10 mg daily, therapeutic lifestyle change, and their
      combination, on the progression of CIMT in those with higher baseline CIMT value but are not
      belong to 'high risk' category, according to the conventional risk factors.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The progress of CIMT</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The progress of ABI</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The progress of PWV</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of atherosclerotic disease</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>P+N</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>placebo without lifestyle intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D+N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 10mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P+A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lifestyle intervention without Atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D+A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lifestyle intervention and Atorvastatin 10mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>atorvastatin 10mg/d</description>
    <arm_group_label>D+N</arm_group_label>
    <arm_group_label>D+A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Aggressive lifestyle intervention</intervention_name>
    <description>aggressive lifestyle intervention</description>
    <arm_group_label>P+A</arm_group_label>
    <arm_group_label>D+A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CIMT is not less than 0.9 mm

          -  without Clinical diagnosis of atherosclerotic disease

          -  without Diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianping Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianping Li</last_name>
    <phone>86-10-66551122</phone>
    <phone_ext>5262</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lijianping@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <last_update_submitted>August 22, 2008</last_update_submitted>
  <last_update_submitted_qc>August 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yong Huo</name_title>
    <organization>Peking University First Hospital</organization>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Therapeutic lifestyle change</keyword>
  <keyword>CIMT</keyword>
  <keyword>ABI</keyword>
  <keyword>PWV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

